Biotech startup Zonova raises £2.1m led by THENA Capital and Angel Academe
This article covers Zonova, a biotech startup, which has raised £2.1m in a seed funding round to accelerate commercialisation of its Z-ROS antimicrobial platform. The funding will support R&D, manufacturing validation and initial licensing partnerships to embed antimicrobial protection into high-volume medical devices such as peripheral and central venous catheters.
Zonova, a biotech startup developing infection-resistant materials for medical devices, has raised £2.1 million in a seed funding round to accelerate commercialisation of its Z-ROS antimicrobial platform. The cash will fund R&D, manufacturing validation and initial licensing partnerships as the company seeks to embed antimicrobial protection into high-volume devices such as peripheral and central venous catheters.
Why it matters
Healthcare-associated infections remain a major global challenge, with medical devices such as catheters and ventilators increasingly implicated in patient harm and associated costs. Antimicrobial resistance is also recognised by global health organisations as a long-term threat to health systems. Technologies that reduce device-associated microbial colonisation and biofilm formation could cut infection rates and lower reliance on antibiotic interventions.
Inside the product
Zonova’s Z-ROS platform integrates antimicrobial functionality directly into medical-device polymers rather than relying on surface coatings or antibiotic release. Early laboratory studies reported greater than 99.99% effectiveness against pathogens including MRSA, E. coli and Pseudomonas aeruginosa. The platform is designed to act without continuous release of active agents and to use a mode of action distinct from antibiotics, which the company says avoids common resistance pathways.
Commercial discussions are under way with device manufacturers to validate manufacturability and performance at scale. Zonova plans to use the funding to expand R&D and commercial teams, advance manufacturing validation, grow its patent portfolio and secure initial OEM licensing partnerships. The company is targeting high-volume vascular access devices as initial application points.
Who are the investors?
The seed round was led by THENA Capital, with a first close by Angel Academe and participation from The Conduit Impact Fund, Arāya Sie Fund, The S100 Club, Animal Health Angels and strategic investors from the healthcare and medical technology sectors. As part of the investment, Pamela Walker Geddes, Founding General Partner at THENA Capital, will join Zonova’s board.
Pamela Walker Geddes, Founding Partner at THENA Capital, said:
Zonova sits at the intersection of three of the most powerful forces shaping the future of healthcare: antimicrobial resistance, advanced materials science, and the urgent need for scalable infection prevention. What impressed us most was not simply the elegance of the science, but the strategic sophistication of the business model. Georgia and the team have built a platform technology capable of integrating into existing global medical device infrastructure with remarkable capital efficiency. That combination of defensible IP, strong clinical relevance, and scalable commercial architecture is exceptionally rare. We believe Zonova has the potential to become foundational infrastructure in next-generation medical devices, enabling manufacturers to dramatically reduce infection risk while supporting a future less dependent on antibiotics. This is precisely the type of world-class, category-defining company THENA was created to back.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
Georgia Fleet and Carla Southworth founded Zonova to move beyond coatings and antibiotic-based fixes by embedding protection into device materials. Georgia Fleet, Co-founder & CEO of Zonova, said:
This funding marks a defining moment for Zonova. We founded the company with the belief that infection prevention in medical devices needed a fundamentally new approach, one that moves beyond coatings, antibiotics, and short term fixes. Our technology has the potential to redefine how medical devices are designed globally by embedding antimicrobial protection directly into the material itself. THENA Capital immediately understood both the scale of the clinical problem and the magnitude of the commercial opportunity. The THENA team brings an exceptional combination of scientific depth, strategic insight, and operational ambition that is incredibly rare in venture. We are thrilled to have them leading this round and joining us as we scale toward major OEM partnerships and international deployment.
The bigger picture
The deal highlights continued investor interest in materials-led approaches to infection prevention and antimicrobial resistance. Zonova’s licensing-led commercial model is intended to allow manufacturers to integrate the technology into existing product lines while maintaining current manufacturing and regulatory pathways, potentially speeding adoption versus routes that require new device approvals.
For the UK and European ecosystem, the round is another example of capital flowing into companies addressing clinical and system-level problems with platform technology and defensible IP. If Zonova can demonstrate manufacturability and clinical benefit at scale, the approach could influence how device makers and regulators view embedded antimicrobial solutions across global markets.
They've invested in Zonova
Get to know these biotech investors
| Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|
 THENA Capital | 1 investment investment | more info | |||
 Angel Academe Network (Angel Academe) | 2 investments investments | more info | |||
 The Conduit Impact Fund | 2 investments investments | more info | |||
 Arāya Sie Fund | 1 investment investment | more info | |||
 The S100 Club | 1 investment investment | more info | |||
 Animal Health Angels | 2 investments investments | more info |
Click here for a full list of 7,589+ startup investors in the UK